Analytical Data
-
Gene name
CCNO
- Application
-
Alternative Names
Cyclin-O; CCNO
-
Species
Human
-
Source
Baculovirus
-
Tag
GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22674-1
-
Expression Region
M1-K350
-
Protein Length
Full Length of Isoform-1
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNO (Cell Cycle-Related Protein No. 1) is a crucial protein that plays a significant role in cell cycle regulation and various cellular processes. Research on recombinant CCNO protein has gained momentum due to its potential implications in understanding cancer biology and cellular proliferation. The protein is known to be involved in the regulation of cell division and has been linked to several cancer types when dysregulated. Scientists are particularly interested in its functional mechanisms, post-translational modifications, and interactions with other cellular proteins, which could provide insights into tumorigenesis and offer potential therapeutic targets. The development of recombinant CCNO through advanced biotechnological methods allows for detailed in vitro and in vivo studies, facilitating a better understanding of its role in disease progression. Furthermore, the ability to produce large quantities of purified CCNO protein paves the way for structural and functional analyses, enabling researchers to explore its potential as a biomarker or target for novel cancer therapies. The study of CCNO and its recombinant forms is thus critical for advancing our knowledge of cell cycle regulation and developing innovative strategies for cancer treatment.
